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Risk assessments are an important element in the management of patients with atrial
fibrillation (AF). In this review, we aim to discuss the concepts and controversies
surrounding the various risk factors for stroke and bleeding in AF. Indeed, there are a
variety of clinical, electrical, biological, and genetic markers to guide stroke and bleeding
risk assessments in AF. The more common factors have been used to formulate risk
stratification scores. Some risk factors have shown promise, but others remain less
well-defined. Our aim is to discuss concepts and controversies surrounding current
evidence of risk factors for stroke and bleeding assessments in AF.
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INTRODUCTION
Risk assessments are an important element in clinical practice. Therefore, it is crucial to understand
the evidence supporting the individual risk factors to help guide management of patients with
complex conditions such as atrial fibrillation (AF). Atrial fibrillation is the most common sustained
cardiac arrhythmia. In 2010, the estimated global prevalence of AF was 33.5 million with
approximately 5 million new cases identified (1). The condition is associated with a greater risk of
stroke and heart failure, reduced quality of life, and a 2-fold increased mortality (1–5). In addition,
it poses a significant healthcare economic burden. Conservative estimates in the United Kingdom
found that AF was associated with a direct annual cost of £459 million, based on an estimated 0.5
million affected patients (6). However, as AF has detrimental effects on many other comorbidities,
the total cost of AF is expected to be significantly higher. A study in the United States on AF-
related cost estimates this to be as high as $26 billion per year (7). Perhaps most worryingly, the
incidence and prevalence of AF is increasing worldwide (8, 9). Between 5.6 and 15.9 million people
in the United States are projected to have AF by 2050 (10, 11) and 17.9 million people in Europe by
2060 (12).
Given the higher stroke risk associated with AF, an integrated approach in the management
of patients with AF must include accurate stroke risk stratification. Patients who are not
identified as “low risk” should then be offered anticoagulation therapy to reduce their risk
of stroke. However, the use of anticoagulation carries an increased risk of bleeding. Most
bleeding events are multifactorial in nature and some may have devastating clinical consequences.
Therefore, it is important to consider and treat any modifiable bleeding risk factors prior to
commencing anticoagulation.
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Overall, stroke and bleeding risk assessments in AF are
complex with ever emerging evidence. Therefore, it can be
challenging for clinicians to stay up to date with the most recent
literature and appreciate the interplay of the various factors
involved. This article is not an exhaustive systematic review of
the vast literature on this topic. Our aim is to discuss concepts
and controversies surrounding current evidence of risk factors
for stroke and bleeding assessments in AF.
STROKE RISK ASSESSMENT
In general, AF is associated with a 5-fold increased risk of
stroke (13). Furthermore, stroke outcomes are more severe in
the presence of AF, as determined by clinical or radiological
assessment (14, 15). Various factors based on clinical, electrical,
biological, and genetic markers have been shown to predict
stroke risk in AF (Table 1, Figure 1). Using a culmination of
different risk factors, predominantly clinical, various authors
have developed a total of at least 15 risk scores to assist stroke
risk stratification in AF (16–19).
At present, the majority of clinical guidelines recommend the
use of CHA2DS2-VASc score to aid decision on anticoagulation
therapy (20–24). This tool was refined from the original 2006
Birmingham “National Institute for Health and Care Excellence”
stroke risk schema with a specific focus on optimal identification
of low-risk individuals and subsequently validated in several large
AF cohorts (18, 25). In general, higher scores are associated with
an increased annual risk of ischemic stroke. Males with a score
of 0 and females with a score of 1 are considered at “low-risk” of
stroke, with event rates<1% per year. Current recommendations
support consideration of anticoagulation therapy in all other
patients where there is sufficient stroke risk to justify the hazards
of anticoagulation.
Older studies have suggested that so-called “lone AF,”
contributes to an annual stroke risk of 1% (26). However, more
contemporary studies have found that stroke rate in such low-
risk patients is <1% per year, as defined by age <65 years and the
absence of any established stroke risk factors (27).
Clinical Markers
Atrial fibrillation is a multi-systemic disorder that often occurs
alongside other comorbidities. Many of these co-morbidities are
risk factors for incident AF and may also increase the risk of
subsequent complications. Pooled analysis from five randomized
controlled trials (RCTs) demonstrated that a history of stroke
or transient ischemic attack (TIA), increasing age, hypertension,
diabetes mellitus, and congestive heart failure were individual
risk factors for stroke in AF (26). A more recent systematic
review of seven studies which included over 12,000 patients
found similar results, although there was inconclusive evidence
to support congestive heart failure and coronary artery disease
as risk factors (28). Prior stroke or TIA was the most powerful
predictor of further stroke events, contributing to an annual risk
of >5%. Increasing age (per decade), hypertension and diabetes
mellitus were each associated with a 1.5–2-fold greater stroke
risk. In a separate study, Olesen et al. demonstrated that the
presence of heart failure, previous stroke, and vascular disease
were independent predictors of stroke or thromboembolism
among AF patients aged under 65 years (29). A Swedish cohort
study found that peripheral artery disease, vascular disease,
prior myocardial infarction, female sex, prior embolism, intra-
cranial hemorrhage (ICH), hypertension, and diabetes mellitus
were associated with additional thromboembolic events (25). The
mechanism by which the conditions above influence stroke risk
in AF is likely multifactorial and partly related to its influence on
progression of the disease through atrial substrate remodeling.
Furthermore, many of these conditions are pro-thrombotic
by nature.
Among non-anticoagulated patients in the ATRIA study,
females had a 60% higher risk of thromboembolism compared
to males (30). Similar findings were shown in a cohort of
anticoagulated patients where females had a 2-fold higher risk
of ischemic stroke (31). However, a subsequent population-based
cohort study of 147,622 patients with AF failed to reproduce these
results (32). A study by Nielsen et al. demonstrated similar rates
of thromboembolism for both sexes among AF patients deemed
TABLE 1 | Risk factors for stroke in AF.
Risk factor Possible risk factor
Clinical
markers
Prior stroke, TIA or TE
Vascular disease+
Increasing age
Congestive heart failure
Hypertension
Diabetes mellitus
Female sex*
Electrical
markers
AF burden
Cardioversion to SR
AF type
AF morphology
BIOLOGICAL MARKERS
Blood
markers
Troponins I and T
BNP and NT-proBNP
Reduced eGFR
D-dimer
Interleukin-6
von Willebrand factor
Mean platelet volume
MMP-2
NOX2-derived peptide
Soluble CD40 ligand
Tumor necrosis factor-α
tPA
β-thromboglobulin
Urine
markers
Albuminuria
Prostaglandin F2α
11-dehydro-thromboxane B2
Imaging
markers
LAA thrombi
LA spontaneous echo contrast
LAA flow velocity
LAA morphology
LV dysfunction
LA enlargement
LA fibrosis
LAA dimensions
Complex aortic plaque
Genetic
marker
Genetic variants on chromosome
4q25
FGB 455 G/A polymorphism
AF, atrial fibrillation; BNP, B-type natriuretic peptide; eGFR, estimated glomerular
filtration rate; LA, left atrial; LAA, left atrial appendage; LV, left ventricle; MMP-2,
matrix metalloproteinase-2; NOX2, reduced nicotinamide adenine dinucleotide phosphate
oxidase 2; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SR, sinus rhythm; TE,
thromboembolism; TIA, transient ischemic attack; tPA, tissue plasminogen activator.
*Risk modifier.
+ Includes prior myocardial infarction, peripheral artery disease, or aortic plaque.
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FIGURE 1 | Central illustration of risk factors associated with stroke in AF. AF, atrial fibrillation; eGFR, estimated glomerular filtration rate; IL-6, interleukin-6; LA, left
atrial; LAA, left atrial appendage; LV, left ventricle; MMP-2, matrix metalloproteinase-2; NOX2, reduced nicotinamide adenine dinucleotide phosphate oxidase 2;
sCD40L, soluble CD40 ligand; SR, sinus rhythm; TE, thromboembolism; TIA, transient ischemic attack; tPA, tissue plasminogen activator; vWF, von Willebrand factor.
*Dashed lines indicate possible risk factors and the size of individual shapes reflect the degree of risk (Created with BioRender).
at lowest risk (33). Excess risk in females were only evident
for those with two or more non-sex-related stroke risk factors.
Therefore, although female sex should remain an important
component for stroke risk assessment in AF, it should be
considered in the context of other risk factors (“risk modifier”).
Electrical Markers
Several electrical markers relating to AF have been described
to predict stroke risk (Table 2). The impact of AF type
(paroxysmal or sustained) on stroke risk remains controversial
with earlier studies reporting a similar risk of stroke and systemic
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TABLE 2 | Electrical markers relating to AF and stroke risk.
References Design Study population n % male; mean
(SD) or median
(IQR) age, years
Relevant outcome
measures
Follow-up
duration
Electrical marker Findings
Chu et al. (34) Retrospective cohort Undergoing pacemaker
implantation
152 56.4;
73.2 (13.3)
Ischemic stroke, TIA or
SE
67 months AF burden Higher AF burden was associated with greater
risk of ischemic stroke, TIA, or SE
Go et al. (35) Retrospective cohort AF on 14-day ambulatory
ECG monitoring
1,965 55.2;
68.8 (11.8)
Ischemic stroke and SE NA
(retrospective)
AF burden Higher AF burden was associated with greater
risk of ischemic stroke or SE
Link et al. (36) Sub-analysis of RCT AF with at least 2 stroke risk
factors
21,105 61.9;
70.6 (NA)
Stroke or SE 2.8 years AF type Paroxysmal AF was associated with lower risk
of stroke or SE compared to persistent and
permanent AF
Boriani et al. (37) Pooled analysis of 5
prospective studies
Pacemaker or ICD in situ 10,016 69;
70 (61–76)
Ischemic stroke 24 months AF burden Higher AF burden was associated with greater
risk of ischemic stroke
Healey et al. (38) RCT Aged ≥65 years, known
HTN and recent pacemaker
or ICD implanatation
2,580 58.4;
76.1 (NA)
Ischemic stroke or SE 2.5 years AHRE
(>190 bpm for
>6min)
Presence of AHREs were associated with a
5.6-fold greater risk of ischemic stroke or SE
Friberg et al. (39) Retrospective cohort AF (or atrial flutter) 1,981 NA;
75.8 (NA)
Ischemic stroke 3.6 years AF type No association with Ischemic stroke
Yilmaz et al. (40) Retrospective cohort AF lasting longer than 24 h 811 45.9;
60 (13)
History of stroke or TIA NA
(retrospective)
Coarse or fine AF Coarse AF was associated with greater risk of
stroke or TIA
Hohnloser et al.
(41)
RCT AF with at least 1 stroke risk
factor
6,706 66;
70.2 (NA)
Stroke or SE 1.3 years AF type No association with stroke or SE
Capucci et al. (42) Prospective cohort Indication for pacemaker
and history of symptomatic
atrial tachyarrhythmias
725 49.7;
71 (11)
Ischemic stroke, TIA or
SE
22 months AF duration AF duration longer than 24 h was associated
with greater risk of ischemic stroke, TIA, or SE
Glotzer et al. (43) RCT SND undergoing
pacemaker implantation
312 45;
74 (NA)
Death of non-fatal
stroke
33.1 months AHRE (>220 bpm
for 10 consecutive
beats)
Presence of AHREs were associated with
greater risk of composite endpoint
Hart et al. (44) Prospective cohort AF 2,012 71.5;
69.1 (NA)
Ischemic stroke 2 years AF type No association with ischemic stroke
AF, atrial fibrillation; AHRE, atrial high rate episode; ECG, electrocardiogram; HTN, hypertension; ICD, implantable cardioverter defibrillator; IQR, interquartile range; NA, not applicable or available; RCT, randomized controlled trial; SD,
standard deviation; SE, systemic embolism; SND, sinus node disease; TIA, transient ischemic attack.
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thromboembolism in paroxysmal AF compared to sustained
or permanent AF (39, 41, 44). These results were supported
by two independent systematic reviews which included a total
of nine relevant studies (28, 45). However, a third systematic
review of 12 studies which included just under 100,000 patients
demonstrated that non-paroxysmal AF was associated with
a hazard ratio of 1.38 [95% confidence interval (CI), 1.17–
1.57] for thromboembolism compared to paroxysmal AF, after
multivariable adjustment (46). The finding was reinforced by
results from the ENGAGE AF-TIMI 48 trial which showed
fewer thromboembolic events among patients with paroxysmal
AF compared to those with sustained AF (36). There was
no difference in thromboembolic risk between patients with
persistent and permanent AF in the study. Given the current
evidence, it would appear that sustained AF is likely to be
associated with a higher stroke risk overall. However, it remains
unclear whether the increased risk is due to shared underlying
mechanisms of the disease or if the burden of AF itself is
directly implicated.
The method(s) by which AF is identified has evolved
significantly over the past decade. While AF was
previously detected predominantly using standard 12-lead
electrocardiogram (ECG), the increased use of implantable
devices has contributed to a rise in “device-detected AF.”
The rise of device-detected AF has also led to new terms
such as “atrial high-rate episodes” (AHRE) and “subclinical
atrial tachyarrhythmias”—both of which are sometimes
used interchangeably with AF. These changes have sparked
important questions such as “what duration of AF is required
for diagnosis?”, “what is the threshold of AF burden where it
becomes clinically important?” and “what is the threshold of
AF burden at which anticoagulation will provide a net benefit?”
While many of these questions remain unanswered, there are
some evidence to shed light on the matter. Several studies
have investigated the threshold of AF burden associated with a
negative clinical outcome. The MOST study found that patients
with at least one AHRE (defined as an atrial rate >220 bpm)
lasting≥5min had a 2-fold risk of stroke or mortality, and 6-fold
risk of developing AF compared to patients without AHRE
(43). The ASSERT study similarly found that subclinical atrial
tachyarrhythmias (defined as an atrial rate >190 bpm) lasting
>6min was associated with an increased risk of incident AF,
and ischemic stroke or systemic embolism (38). In contrast,
Capucci et al. performed a study using pre-specified AF
durations in which the authors demonstrated that AF duration
of >5min was not associated with thromboembolic events
unlike episodes >24 h which were independently associated
with thromboembolic events (42). A potential explanation for
the differences observed in this study may be related to the fact
that a significant proportion of patients had short episodes of
AF (about 80%). Pooled analysis of five prospective studies that
included 10,016 patients with implantable devices found that AF
burden was an independent predictor of ischemic stroke (37).
In this study, patients with 1 h of AF per day were found to be
at highest risk. Among patients with paroxysmal AF, authors
of the KP-RHYTHM study reported a 3-fold increased risk of
thromboembolism in those with the highest tertile of AF burden
(≥11.4%) compared to the lower two tertiles, after adjusting for
either ATRIA or CHA2DS2-VASc score (35). A further study
in patients with dual-chamber pacemakers also confirmed that
patients with thromboembolism had higher AF burden (34).
Overall, AF burden may reflect the proportion of time spent
in mechanical dyssynchrony, thereby promoting thrombus
formation. Though it is recognized to be an important predictor
of stroke risk, the exact relationship remains to be defined and
further research is warranted. Furthermore, determining the
AF burden in patients without implantable cardiac devices can
be challenging.
There are also important considerations when treating
patients with a high burden of AF. Although a strategy to reduce
this burden may be appropriate for some patients, attempts
to restore sinus rhythm is not without risk. The FibStroke
study revealed that electrical and pharmacological cardioversions
were related to occurrences of ischemic stroke (47). As the
majority of events occurred in patients who underwent electrical
cardioversion, it could be postulated that the delivery of electrical
energy may have dislodged pre-formed thrombi. However, many
of the stroke events only occurred after a significant time delay
(median of 2 days) following cardioversion. Therefore, there
are likely to be other factors involved. Furthermore, there are
even reports of acute thromboembolic complications following
spontaneous cardioversion of AF (48, 49). A potential cause for
this may be linked to atrial stunning that occurs regardless of the
means of cardioversion (50).
It was previously suggested that the morphology of AF as
assessed on ECG may be useful for stroke risk assessment. In
a study of 811 consecutive patients, Yilmaz et al. classified AF
based on surface ECG as “coarse” or “fine” AF, and was able to
demonstrate that patients with coarse AF had increased risk of
stroke (40). The authors defined “coarse” AF as the presence of
undulations moving ≥1mm from the isoelectric baseline with
different morphologies and “fine” AF as the presence of minimal
or no undulation from the isoelectric baseline. At present, there is
insufficient evidence to draw any firm conclusions. Nevertheless,
if deemed reliable, classification of AF according to the different
morphologies on ECG may provide a readily assessible tool to
support clinical decisions.
Given the increased risk of stroke in AF, it would seem
plausible that a temporal relationship might exists between
these two conditions. If true, it may provide us a method
of identifying patients at the point of highest stroke risk in
order to instigate additional protective measures to avoid this
complication. However, an initial study by ASSERT investigators
revealed that only 8% of patients had subclinical AF detected
within 30 days before their stroke or systemic embolism (51).
Thus far, there is no strong evidence to support a temporal
relationship between the episodes of AF and stroke events.
Biological Markers (“Biomarkers”)
Many biomarkers involving blood, urine, and structural
parameters have been studied in AF and been shown to improve
the accuracy of stroke risk stratification. Despite this, their
clinical applicability remains limited. Possible reasons include
inter- and intra-patient and assay variability; diurnal variation
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of the results obtained; costs involved; strong influences
of associated comorbidities and treatments in AF on these
parameters; and lack of specificity. As such, these biomarkers are
mainly reserved for research purposes.
Blood-Based Biomarkers
In general, blood-based biomarkers may be divided into those
that relate to cardiac function (troponins and natriuretic
peptides), hemostatic processes [D-dimer, von Willebrand
factor (vWF), soluble E-selectin, and P-selectin], inflammation
[interleukin-6 (IL-6) and C-reactive protein (CRP)], or “others”
(renal function) (Table 3).
Cardiac function
Troponins and natriuretic peptides are among the most
frequently used cardiac biomarkers. Their value in a variety
of cardiovascular diseases such as myocardial infarction and
heart failure have previously been established (80, 81). Further
studies have also consistently demonstrated that levels of these
biomarkers may be used to improve predictions of stroke risk in
AF (57, 62, 65–67, 71). A RE-LY sub-study found that elevations
in troponin I andN-terminal pro-B-type natriuretic peptide (NT-
proBNP) were common among AF patients (66). Both were
independently related to an increased risk of stroke and there
was a graded relationship such that patients with higher levels
of these cardiac biomarkers were at greater risk compared to
those with lower levels. The highest quartile of NT-proBNP
was associated with 2.4-fold greater risk of stroke compared
to the lowest quartile while the higher tertile of troponin I
was associated with a 2.0-fold greater risk of stroke compared
to the lowest tertile. There are several proposed mechanisms
for the prognostic value of these cardiac biomarkers. In AF,
unlike heart failure, B-type natriuretic peptides (BNPs) may
originate from the atria (82). This is supported by the fact
that restoration of sinus rhythm is associated with a rapid
fall in the level of natriuretic peptides (83, 84). The elevated
levels of natriuretic peptides may reflect the degree of atrial
stretch (85). This in turn indicates atrial dysfunction which
is linked to thrombus formation (86). Meanwhile, troponins
are released as a following myocardial injury which may
promote a pro-thrombotic state. Furthermore, elevated levels
of troponin has been associated with impaired left atrial
function, as assessed by cardiac magnetic resonance imaging
(MRI) (87).
Renal function
Another important biomarker in stroke risk stratification is
renal function (17, 61, 63, 73). Impaired renal function was
demonstrated to be a strong predictor of stroke and systemic
embolism in the ROCKET AF and ATRIA study cohorts, second
only to prior stroke or TIA (17). A meta-analysis of 18 studies
involving 538,479 patients with AF demonstrated that estimated
glomerular filtration rate (eGFR) was an independent risk factor
for stroke or systemic embolism, with worsening chronic kidney
disease (CKD) being associated with a greater increased risk (88).
Indeed AF patients with the most severe form of CKD requiring
dialysis may have a dramatic increase of 9.8-fold in stroke risk
(89). Chronic kidney disease promotes a pro-thrombotic state by
its effects on the individual components of Virchow’s triad (90). It
has been found to be associated with stasis of the left atrium (LA)
(91, 92), impaired endothelial function (93–97) and enhanced
platelet activation (98, 99). Furthermore, CKD is linked to the
release of procoagulant and inflammatory biomarkers (99–101).
It was previously suggested that the inclusion of CKD as a
risk factor may improve stroke prediction models (17). However,
additional studies have found that it did not improve the
discriminative capabilities of the CHADS2 and CHA2DS2-VASc
scores (63, 102, 103). To summarize prior results, a meta-
analysis of eight studies found that the inclusion of CKD
resulted in a slight improvement for stroke prediction by the
CHADS2 score but not with the CHA2DS2-VASc score (88).
Therefore, there is currently insufficient evidence to justify the
addition of CKD to the guideline-recommended CHA2DS2-
VASc score. This is perhaps unsurprising given that CKD is
associated with the individual component risk factors within the
CHA2DS2-VASc score.
Hemostasis
Stroke risk in AF is strongly related to the disruption of
hemostasis, leading to a pro-thrombotic state. However, the
hemostatic processes are complex and involve many different
pathways. Therefore, it is important to understand which of
these are affected in AF. D-dimer is a small protein fragment
that is released following fibrinolysis. A prospective study of
509 patients with AF, found that those with a D-dimer level
of <150 ng/ml had significantly lower risk of thromboembolic
events compared to those with D-dimer level of ≥150 ng/ml,
0.7% per year compared to 3.8% per year (76). Similar findings
were demonstrated in other studies (72, 78). In contrast, You
et al. reported that D-dimer was not an independent risk factor
for ischemic stroke in AF despite finding a positive correlation
between D-dimer levels and stroke risk scores (CHADS2 and
CHA2DS2-VASc) (55). However, this study was retrospective in
nature and only included non-anticoagulated patients. Overall,
it does appear that D-dimer may be helpful for stroke risk
stratification in AF.
Given the role of platelets in hemostasis, it would seem
likely that platelet count may be associated with stroke risk.
However, in a study of 124 patients with AF on non-vitamin K
oral anticoagulants (NOAC), Janion-Sadowska et al. found no
association between thrombocytopenia (platelet count <100 ×
109/L) and the risk of stroke or TIA over a 55-month follow-up
period (53). In contrast, Park et al. recently reported retrospective
registry data on 10,978 patients with AF where patients with
a platelet count <100 × 109/L had a significantly lower stroke
risk compared to those with a normal platelet count (52). A
major difference between the trials was in terms of the use
of anticoagulation. About half of the patients (55.4%) in the
latter trial were not anticoagulated and among those who were,
warfarin was the main agent of choice (96.8%). There is limited
evidence to base any firm conclusions at present although it could
be that thrombocytopenia is protective against stroke in AF.
VonWillebrand factor is a glycoprotein integral to hemostasis.
Raised levels of vWF has been associated with a pro-thrombotic
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TABLE 3 | Blood-based biomarkers for stroke risk in AF.
References Design Study population n % male; mean
(SD) or median
(IQR) age, years
Relevant outcome
measures
Follow-up
duration
Biomarker Findings
Park et al. (52) Prospective
registry
AF 10,978 63.6;
73.5 (11.8)
Stroke 42.6 months Platelet count
(<100 × 109/L)
Lower platelet counts were associated with
lower risk of stroke
Janion-Sadowska
et al. (53)
Prospective
cohort
AF on NOAC 124 33.1;
70.3 (NA)
Stroke or TIA 55 months Platelet count
(<100 × 109/L)
No association with stroke or TIA
Rivera-Caravaca
et al. (54)
Prospective
cohort
AF on OAC,
attending clinic
1,226 49.7;
76 (70–81)
Ischemic stroke 6.5 years Soluble fibrin
monomer complex
No association with ischemic stroke
You and Tang (55) Case-
controlled
study
Non-
anticoagulated
AF
323 63.8;
75.2 (NA)
Ischemic stroke NA
(retrospective)
D-dimer No association with ischemic stroke
Ancedy et al. (56) Prospective
cohort
Hospitalized AF 122 46;
70 (14)
Composite of all-cause
death and stroke;
stroke
5 years vWF Higher vWF levels were associated with greater
risk of composite endpoint
No association with stroke risk only
Hayashi et al. (57) Prospective
registry
AF 1,013 71.6;
72.8 (9.7)
Stroke, TIA, or SE 25 months BNP High BNP levels were associated with a
3.9-fold greater risk of stroke, TIA, or SE
Choi et al. (58) Prospective
cohort
AF 352 57.4;
68.4 (12.1)
Composite of ischemic
stroke and incidental
LA thrombus
35.4 months Antithrombin III No association with composite endpoint
MPV High MPV levels were associated with a
6.4-fold greater risk of composite endpoint
Aulin et al. (59) Sub-study of
RCT
AF with at least 1
stroke risk factor
6,187 63.7;
72 (67–77)
Stroke or SE 2 years IL-6 Higher IL-6 levels were associated with greater
risk of stroke or SE
CRP No association with stroke or SE
Fibrinogen No association with stroke or SE
Pignatelli et al. (60) Prospective
cohort
AF 950 55.5;
73.3 (8.8)
Composite of stroke,
TIA, MI, and coronary
revascularization
25.7 months Serum
NOX2-derived
peptide
Higher serum NOX2-derived peptide levels
were associated with greater risk of composite
endpoint
Banerjee et al. (61) Prospective
cohort
AF 5,912 62.9;
70.9 (NA)
Ischemic stroke or TE 2.5 years eGFR (MDRD) Lower levels of renal function were associated
with greater risk of ischemic stroke or TE
Roldan et al. (62) Prospective
cohort
AF on OAC,
attending clinic
1,172 49;
76 (71–81)
Stroke or TIA 34 months NT-proBNP High NT-proBNP levels were associated with a
2.7-fold greater stroke or TIA risk
Apostolakis et al.
(63)
Post-hoc
analysis of
RCT
AF 4,576 66.5;
70 (9)
Stroke or SE 10.8 months CrCl, eGFR
(MDRD, CKD-EPI)
Lower levels of renal function were associated
with greater risk of stroke or SE
Krishnamoorthy
et al. (64)
Prospective
cohort
AF, attending clinic 423 55.6;
72.7 (8.4)
Composite of stroke,
acute MI, and all-cause
mortality; Ischemic
stroke
19 months vWF Higher vWF levels were associated with greater
risk of composite endpoint and Ischemic stroke
Soluble E-selectin Higher soluble E-selectin levels were
associated with greater risk of composite
endpoint and Ischemic stroke
Hijazi et al. (65) Sub-study of
RCT
AF with at least 1
CHADS2 risk
factor
14,892 64.4;
NA
Stroke or SE 1.9 years NT-proBNP Higher NT-proBNP levels were associated with
greater risk of stroke or SE
(Continued)
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TABLE 3 | Continued
References Design Study population n % male; mean
(SD) or median
(IQR) age, years
Relevant outcome
measures
Follow-up
duration
Biomarker Findings
Highest quartile of NT-proBNP was associated
with 2.4-fold greater risk of stroke or SE
compared to lowest quartile
Piccini et al. (17) Sub-study of
RCT
AF with at least 1
stroke risk factor
14,264 60.7;
73 (NA)
Stroke or SE 1.9 years CrCl, eGFR
(MDRD)
Lower levels of renal function were associated
with greater risk of stroke or SE; every
10-mL/min decrease in CrCl resulted in
1.12-fold increase in risk; every 5 mL/min/1.73
m2 decrease in eGFR (MDRD) resulted in
1.09-fold increase in risk
Hijazi et al. (66) Sub-study of
RCT
AF with at least 1
stroke risk factor
6,189 63.7;
72 (67–77)
Stroke 2.2 years NT-proBNP Higher NT-proBNP levels were associated with
greater stroke risk
Highest quartile of NT-proBNP was associated
with 2.4-fold greater risk of stroke compared to
lowest quartile
Troponin I Higher troponin I levels were associated with
greater stroke risk
Highest quartile of troponin I was associated
with 2.0-fold greater risk of stroke compared to
lowest quartile
Roldan et al. (67) Prospective
cohort
AF on OAC,
attending clinic
930 51;
76 (70–81)
Stroke or TIA 2 years Troponin T High troponin T levels were associated with a
2.4-fold greater stroke or TIA risk
IL-6 No association with stroke or TIA
Ehrlich et al. (68) Prospective
cohort
AF 278 63;
70 (11)
Composite of stroke,
MI, SE, and all-cause
death
28 months hsCRP No association with composite endpoint
sCD40L No association with composite endpoint
MMP-2 Higher MMP-2 levels were associated with
greater risk of composite endpoint
vWF No association with composite endpoint
sVCAM-1 Higher sVCAM-1 levels were associated with
greater risk of composite endpoint
Roldan et al. (69) Prospective
cohort
AF on OAC,
attending clinic
829 50;
76 (70–80)
Composite of TE, acute
MI, and acute HF
27.6 months vWF High vWF levels were associated with a greater
risk of composite endpoint
Ha et al. (70) Prospective
cohort
AF 200 56;
68.9 (11.7)
Ischemic stroke 15.1 months MPV Higher MPV levels were associated with greater
ischemic stroke risk
Highest tertile of MPV was associated with a
5.0-fold greater risk of ischemic stroke
compared to lowest quartile
Sadanaga et al.
(71)
Post-hoc
analysis of
prospective
cohort
AF on OAC 261 56;
74 (9)
Ischemic stroke, TIA, or
SE
24.7 months BNP High BNP levels were associated with a
5.3-fold greater risk of ischemic stroke, TIA, or
SE
Sadanaga et al.
(72)
Prospective
cohort
AF on OAC 269 57;
74 (9)
Ischemic stroke, TIA, or
SE
25.2 months D-dimer High D-dimer levels were associated with a
15.8-fold greater risk of ischemic stroke, TIA, or
SE
(Continued)
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TABLE 3 | Continued
References Design Study population n % male; mean
(SD) or median
(IQR) age, years
Relevant outcome
measures
Follow-up
duration
Biomarker Findings
Go et al. (73) Sub-study of
prospective
cohort
AF 10,908 57.2;
71.6 (NA)
TE 3 years eGFR (MDRD) Lower levels of renal function were associated
with greater TE risk
Pinto et al. (74) Prospective
cohort
Chronic AF 373 63.5;
66.1 (7.4)
Ischemic stroke 3 years IL-1β No association with ischemic stroke
TNF-α Higher TNF-α levels were associated with
greater ischemic stroke risk
IL-6 Higher IL-6 levels were associated with greater
ischemic stroke risk
IL-10 No association with ischemic stroke
E-selectin No association with ischemic stroke
P-selectin No association with ischemic stroke
ICAM-1 No association with ischemic stroke
VCAM-1 No association with ischemic stroke
vWF Higher vWF levels were associated with greater
ischemic stroke risk
Ferro et al. (75) Prospective
cohort
AF 231 48;
72.4 (10.3)
Composite of stroke
and MI
27.8 months sCD40L High sCD40L levels were associated with a
4.6-fold greater risk of composite endpoint
Nozawa et al. (76) Prospective
cohort
AF 509 64.8;
66.6 (10.3)
Composite of clinically
evident stroke, TIA, and
SE
2 years D-dimer High D-dimer levels were associated with a
greater risk of composite endpoint
F1+2 No association with composite endpoint
Platelet factor 4 No association with composite endpoint
β-thromboglobulin No association with composite endpoint
Conway et al. (77) Prospective
cohort
AF, attending clinic 77 57;
68 (62–75)
Stroke 6.3 years IL-6 High IL-6 levels were associated with a 2.9-fold
greater stroke risk
CRP No association with stroke
Vene et al. (78) Prospective
cohort
AF referred to
clinic for initiation
of OAC
113 60;
70.2 (5.4)
Composite of stroke,
MI, SE, peripheral
vascular occlusion, and
cardiovascular death
44.3 months D-dimer Higher D-dimer levels were associated with
greater risk of composite endpoint
tPA Higher tPA levels were associated with greater
risk of composite endpoint
F1+2 No association with composite endpoint
TAT complexes No association with composite endpoint
PAI-1 No association with composite endpoint
Feinberg et al. (79) Sub-study of
prospective
cohort
AF with at least 1
high-risk stroke
factor
1,531 NA;
70 (NA)
Ischemic stroke or SE 2 years F1+2 No association with ischemic stroke or SE
β-thromboglobulin No association with ischemic stroke or SE
Fibrinogen No association with ischemic stroke or SE
Factor V Leiden
mutation
No association with ischemic stroke or SE
AF, atrial fibrillation; BNP, B-type natriuretic peptide; CrCl, creatinine clearance; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; F1+2, prothrombin fragment F1+2; hsCRP, high-sensitivity C-reactive protein; ICAM-1,
intercellular adhesion molecule-1; IL-10, interleukin-10; IL-1β, interleukin-1β; IL-6, interleukin-6; IQR, interquartile range; LA, left atrial; MDRD, Modification of Diet in Renal Disease Study; MI, myocardial infarction; MMP-2, matrix
metalloproteinase-2; MPV, mean platelet volume; NA, not applicable or available; NOAC, non-vitamin K oral anticoagulants; NOX2, reduced nicotinamide adenine dinucleotide phosphate oxidase 2; NT-proBNP, N-terminal pro-B-type
natriuretic peptide; OAC, oral anticoagulation; PAI-1, plasminogen activator inhibitor-1; RCT, randomized controlled trial; sCD40L, soluble CD40 ligand; SD, standard deviation; SE, systemic embolism; sVCAM-1, soluble vascular cell
adhesion molecule-1; TAT, thrombin-antithrombin; TE, thromboembolism; TIA, transient ischemic attack; TNF-α, tumor necrosis factor-alpha; tPA, tissue plasminogen activator; vWF, von Willebrand factor.
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Ding et al. Risk Assessments in AF
state in AF (56, 64, 69, 74). However, a limitation in many of
these studies was that the primary outcome measure included
events such as heart failure and all-cause death. Therefore, it
was difficult to draw strong conclusions from them. Among
those that evaluated stroke only outcomes, two studies found
that high levels of vWF was linked to a greater risk of stroke
(64, 74). Despite demonstrating that higher levels of vWF were
associated with a greater composite risk of all-cause death and
stroke, Ancedy et al. found that the results were not significant
when evaluated for stroke events only (56). Consequently,
the role of vWF for stroke risk stratification in AF requires
additional investigation.
Inflammation
There is ample evidence to support the importance of
inflammation in AF. However, use of inflammatory biomarkers
to predict stroke risk in this condition has been met with
conflicting results. An early pilot study demonstrated that IL-
6 was an independent predictor of stroke risk in AF, but not
CRP (77). Subsequently, Pinto et al. evaluated this by comparing
plasma levels of interleukin-1β, tumor necrosis factor-alpha,
IL-6 and interleukin-10 (and E-selectin, P-selectin, intercellular
adhesion molecule-1, vascular cell adhesion molecule-1 and
vWF) in chronic AF patients with and without new-onset
ischemic stroke over a period of 3 years (74). Following
multivariable adjustment, only IL-6 and tumor necrosis factor-
alpha remained significant predictors of stroke risk. In a separate
study, Aulin et al. postulated that levels of inflammatory
markers (IL-6, CRP, and fibrinogen) may be related to the
risk of thromboembolism in AF (59). After adjustment for
clinical risk factors, only IL-6 was found to be significant.
However, use of other biomarkers (troponin, NT-proBNP, and
cystatin-C) attenuated the importance of IL-6 such that it
was no longer predictive of stroke risk in AF. Other studies
failed to demonstrate an association between thromboembolic
risk in AF and levels of high-sensitivity CRP (68), IL-
6 (67), or fibrinogen (79). Given the current evidence,
it appears that high levels of underlying inflammation as
detected by IL-6 indicates a pro-thrombotic state in AF.
There is no indication that CRP or fibrinogen are useful for
this purpose.
In addition to the biomarkers mentioned above, there
are others that have been evaluated in AF. Many have
limited supporting evidence and require further studies to
confirm their possible predictive capabilities. These include
mean platelet volume, matrix metalloproteinase-2, reduced
nicotinamide adenine dinucleotide phosphate oxidase 2-derived
peptide, soluble CD40 ligand and tissue plasminogen activator
(58, 60, 68, 70, 75, 78). There are also biomarkers that have not
been thoroughly evaluated but thus far not been convincingly
shown to be associated with stroke risk in AF. These include
soluble fibrin monomer complex, antithrombin III, E-selectin,
P-selectin, intercellular adhesion molecule-1, vascular cell
adhesion molecule-1, prothrombin fragment F1+2, thrombin-
antithrombin complexes, plasminogen activator inhibitor-1, and
β-thromboglobulin (54, 58, 64, 68, 74, 76, 78, 79).
Urine Biomarkers
Few urine biomarkers have been identified as possible predictors
of stroke risk in AF. In the ATRIA study, presence of
proteinuria was associated with a 1.5-fold increased risk of
thromboembolism (73). In addition, a retrospective study
demonstrated that higher levels of albuminuria were associated
with greater risk of thromboembolism among patients with
newly diagnosed AF (104). Possible mechanisms are: (1)
albuminuria reflects early-stage CKD which has been shown
to be related to stroke risk; (2) albuminuria causes an
imbalance between naturally occurring pro-thrombotic and anti-
thrombotic factors, such as that seen in nephrotic syndrome
(105). Pignatelli et al. showed that higher urinary prostaglandin
F2α levels were associated with a greater composite risk of stroke,
TIA, myocardial infarction and coronary revascularisation
during a follow-up period of 26 months (60). Furthermore,
urinary 11-dehydro-thromboxane B2 has also been found to be
related to a composite risk of stroke, TIA, myocardial infarction,
coronary revascularisation, and cardiovascular-related death
among patients with AF (106). Overall, although urine
biomarkers have not been comprehensively investigated in AF,
they may represent an additional, simple, and non-invasive
method to aid stroke risk stratification.
Structural Biomarkers
Atrial fibrillation causes significant structural changes including
atrial remodeling that may be detected through a variety
of imaging techniques. Some of these changes have been
found to predict stroke risk in AF (Table 4), potentially
by promoting abnormal blood stasis. Early studies in this
area have relied predominantly on standard transthoracic
echocardiography. Recently, advanced imaging modalities with
increased accuracy such as trans-esophageal echocardiography,
computed tomography, and MRI have become more widely
available. This has allowed the discovery of new structural
biomarkers such as LA fibrosis and left atrial appendage (LAA)
morphology that may be used to refine stroke risk assessment in
AF. The SPAF study evaluated the role of 14 echocardiographic
parameters to predict incident ischemic stroke or systemic
embolism in AF (117). The authors reported that the presence
of left ventricular dysfunction and higher LA size were found
to be important. Furthermore, these parameters were able to
identify patients without clinical risk factors who were at higher
risk of stroke. A prospective study of 2,713 patients with AF
demonstrated that LA enlargement (>45mm) was linked to a
1.7-fold increased risk of ischemic stroke or systemic embolism
(108). Dakay et al. also found that more severe LA enlargement
was associated with a greater risk of ischemic stroke despite
anticoagulation (107). Interestingly, there appears to be an
association between LA size and stroke risk even in the absence
of AF. In the Framingham Heart study, non-AF patients with
increased LA size were found to be at greater risk of stroke
and mortality during the follow-up period of 8 years (118). The
presence of LA enlargement may therefore be helpful to identify
the subset of AF patients who remain at high-risk of stroke
despite anticoagulation therapy. Furthermore, it can be assessed
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TABLE 4 | Structural biomarkers for stroke risk in AF.
References Design Study population n % male; mean
(SD) age, years
Relevant
outcome
measures
Follow-up
duration
Biomarker Findings
Dakay et al.
(107)
Prospective cohort AF hospitalized with
ischemic stroke
225 44.4;
79.5 (10.5)
Anticoagulation
failure
NA LAE More severe left atrial enlargement was associated with
greater risk of anticoagulation failure resulting in stroke
Hamatani
et al. (108)
Prospective
registry
AF 2,713 60.2;
73.7 (NA)
Ischemic stroke or
SE
32.6 months LAE LA diameter >45mm was associated with a 1.7-fold
greater risk of ischemic stroke or SE
Kong et al.
(109)
Prospective cohort Drug-refractory AF
undergoing catheter
ablation
219 65.3;
58.1 (NA)
Stroke NA
(retrospective)
LAA morphology Non-chicken wing morphology was associated with
5.8-fold greater stroke risk
Khurram et al.
(110)
Prospective cohort AF referred for catheter
ablation
678 74.8;
59.5 (9.7)
Stroke or TIA NA
(retrospective)
LAA morphology No association with stroke or TIA
LAA trabeculations Extensive LAA trabeculation was associated with a
greater stroke or TIA risk
LAA orifice diameter Smaller LAA orifice was associated with a greater stroke
or TIA risk
LAA length Shorter LAA length was associated with a greater stroke
or TIA risk
Kimura et al.
(111)
Case-controlled
study
Drug-refractory AF who
underwent catheter
ablation
80 82.5;
58.6 (6.0)
Stroke NA
(retrospective)
LAA morphology Cauliflower morphology was associated with a greater
stroke risk
Di Biase et al.
(112)
Prospective cohort Drug-refractory AF
undergoing catheter
ablation
932 79;
59 (10)
Ischemic stroke or
TIA
NA
(retrospective)
LAA morphology Chicken wing morphology was associated with lowest
risk of ischemic stroke or TIA; with chicken wing
morphology as reference, cactus, windsock and
cauliflower were associated with a 4.1-, 4.5-, and
8.0-fold greater risks of ischemic stroke or TIA,
respectively
Beinart et al.
(113)
Case-controlled
study
Non-anticoagulated AF 144 75;
54.5 (9.9)
Stroke or TIA NA
(retrospective)
LAA volume No association with stroke or TIA
LAA depth No association with stroke or TIA
LAA neck dimensions High LAA neck dimension was associated with greater
stroke or TIA risk
LAA number of lobes No association with stroke or TIA
Goldman
et al. (114)
Sub-study of
prospective cohort
AF with at least 1
high-risk stroke factor*
721 76;
68 (9)
Ischemic stroke or
SE
NA LAA peak antegrade
flow velocity
LAA peak antegrade flow velocity <20 cm/s was
associated with greater risk of Ischemic stroke or SE
Zabalgoitia
et al. (115)
Sub-study of
prospective cohort
AF with at least 1
high-risk stroke factor*
786 76;
69 (9)
Ischemic stroke or
SE
NA LAA thrombus Presence of LAA thrombus was associated with a
2.5-fold greater risk of Ischemic stroke or SE
SEC Presence of SEC was associated with a 3.7-fold greater
risk of Ischemic stroke or SE
LAA peak antegrade
flow velocity
LAA peak antegrade flow velocity <20 cm/s was
associated with a 1.7-fold greater risk of Ischemic stroke
or SE
Complex aortic plaque Presence of complex aortic plaque was associated with
a 2.1-fold greater risk of Ischemic stroke or SE
Leung et al.
(116)
Prospective cohort AF undergoing TOE 272 68;
68 (11)
Stroke or SE 17.5 months LA SEC Presence of LA SEC was associated with a 3.5-fold
greater risk of stroke or SE
SPAF (117) Sub-study of RCT AF 568 70;
67 (12)
Ischemic stroke or
SE
1.3 years 14 echocardiographic
parameters
LV dysfunction and higher LA size were the associated
with greater risk of Ischemic stroke or SE
AF, atrial fibrillation; IQR, interquartile range; LA, left atrial; LAA, left atrial appendage; LAE, left atrial enlargement; LV, left ventricular; NA, not applicable or available; RCT, randomized controlled trial; SD, standard deviation; SE, systemic
embolism; SEC, spontaneous echo contrast; TIA, transient ischemic attack; TOE, trans-esophageal echocardiography.
*Similar study cohort.
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on transthoracic echocardiography without the need for more
complex imaging techniques.
The majority of cardioembolic strokes originate from the
left atrium. In the LA, the most common site of thrombus
formation is within the LAA. This is a small, complex, pouch-
like sac attached to the anterior portion of the LA. Due to its
complex anatomical structure and narrow inlet, the LAA is prone
to abnormal blood stasis predisposing to thrombus formation.
These thrombi may subsequently dislodge to cause a stroke.
Therefore, it is perhaps unsurprising that certain LAA features
have been shown to influence stroke risk. Unfortunately, these are
rarely appreciated on standard transthoracic echocardiography
which remains the most commonly used imaging method. The
SPAF-III study demonstrated that among AF patients, ongoing
arrhythmia during trans-esophageal assessment was associated
with a lower LAA peak antegrade flow velocity (Avp) (114).
Furthermore, the authors found that an LAA Avp <20 cm/s was
related to the presence of spontaneous echo contrast and LAA
thrombus, and increased risk of cardioembolic events. Predictors
of Avp <20 cm/s were increasing age, higher systolic blood
pressure, ischemic heart disease, and greater LA area. All of
which are known risk factors for AF. In addition, the presence
of spontaneous echo contrast and LAA thrombus have both been
independently shown to be linked to greater stroke risk in AF
(115, 116).
It is now recognized that the LAA is a complex structure with
significant variation between patients. A study by Di Biase et al.
found that among AF patients planned for catheter ablation, LAA
morphologies could be categorized into four main groups based
on their appearances on computed tomography or MRI (112).
In order of reducing frequency, these were called “chicken wing”
(48%), “cactus” (30%), “windsock” (19%), and “cauliflower” (3%).
After multivariable adjustment, a chicken wing morphology
was associated with the lowest risk of stroke. In comparison,
there was a 4-fold increased stroke risk with the cactus and
windsock morphologies, and 8-fold increased stroke risk with
the cauliflower morphology. Similar findings were also reported
elsewhere (109, 111). However, a study by Khurram et al. failed to
demonstrate any association between LAA morphology and risk
of stroke or TIA (110). In addition, the authors found that there
was significant inter-observer variability during determination
of LAA morphology, indicating that this may be an unreliable
method of assessment. Limitations of the studies assessing LAA
morphology above lies in the fact that they were all retrospective
in nature and included only a subset of AF patients, specifically
those undergoing catheter ablation. Therefore, future prospective
studies are needed to confirm whether LAA morphology may
be used for stroke risk stratification in a general cohort of
AF patients.
Other LAA parameters such as the number of lobes, neck
dimension, overall dimension, volume, orifice diameter, and
trabeculations have also been studied but again further evaluation
is required (110, 113). Left atrial fibrosis may also represent
an additional biomarker for stroke risk stratification. In a
study of 178 patients with AF, LA fibrosis was assessed using
late gadolinium enhancement MRI and correlated to trans-
esophageal findings (119). The authors reported that high atrial
fibrosis (>20%) was linked to spontaneous echo contrast and
LAA thrombus. Additionally, the presence of complex aortic
plaques on trans-esophageal echocardiography defined based
on features of mobility, ulceration, pedunculation, thickness
≥4mm, and location were found to be independently associated
with a 2-fold increased thromboembolic risk (115).
Genetic Markers
Improvements in genomic technologies have seen an increasing
role for genetic testing in certain diseases. This may provide
an additional element for risk stratification in AF. However,
there have been few genetics studies in AF to date and they
have largely focused on chromosome 4q25. It has been suggested
that genetic variants on this chromosome may be related with
ischemic stroke (120, 121). In a case-control study of 1,059
AF patients, after adjusting for potential confounders, FGB 455
G/A polymorphism was associated with increased cardioembolic
stroke potentially through elevated fibrinogen levels (122). Factor
V Leiden mutation has not been found to be predictive of
thromboembolism in AF (79). Overall, more studies are needed
to confirm these genetic findings. Even then, the use of genetic
markers for stroke risk stratification in AF remains unrealistic
at present.
BLEEDING RISK ASSESSMENT
A vital aspect of the management for AF includes stroke
prevention. To this end, many patients require anticoagulation
therapy. However, this approach is not without risk. A meta-
analysis of eight RCTs found that the annual rates of major
bleeding varied from 1.4 to 3.4% among patients with AF treated
with warfarin (123). The risk of ICH, the most serious form of
bleeding, was estimated at 0.61% per year. Similar results were
reported by Fang et al. in a cohort of 13,559 patients with AF
treated with warfarin (124). Despite the relatively low rates of
ICH, 76% of these patients had severe disability or died, and
ICH was associated with at least a 20-fold increased risk of 30-
day mortality compared to other forms of bleeding. Given the
detrimental consequences of anticoagulation-related bleeding in
AF, especially with ICH, efforts should be directed at reducing
this risk while maintaining adequate stroke prevention. The use
of NOACs have been shown to be superior to warfarin in this
regard. Two large meta-analysis have shown that NOACs, as a
class of medications, have a better safety profile with less major
bleeding and ICH when compared to warfarin (125, 126).
It is also important to consider the timing of anticoagulation-
related bleeding events. In this aspect, there appears to be an
excess risk during the initial few months of treatment with
vitamin K antagonist (VKA) (127). This may be due to poor
anticoagulation control that eventually improves with time.
However, there are likely to be additional factors involved as
a similar effect was observed with dabigatran, where initial
dose adjustments are rare (128). It is possible that the use
of anticoagulation is simply unmasking high-risk individuals
who were not identified using traditional assessment methods.
Therefore, better risk profiling is necessary. Various factors based
on clinical, biological, and genetic markers have been shown to
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predict the risk of anticoagulation-related bleeding in patients
with AF (Table 5). Some of these factors may also influence the
stroke risk.
There are several bleeding risk scores designed specifically
for use in an AF cohort (Table 6). They have previously been
summarized and include a combination of different clinical,
biological and genetic markers (132). In general, each risk factor
is assigned a score and the sum of these scores are used to estimate
annual bleeding risk in an individual who is anticoagulated. It
should be noted that there are differences in the way certain risk
factors (e.g., age, renal dysfunction, and hypertension) have been
defined between the various risk scores. Furthermore, many risk
factors for bleeding contribute as well to stroke risk in AF. This
highlights the complex relationship between thrombogenesis
and bleeding, and represent the challenges faced by physicians
when weighing up the risk and benefits of anticoagulation
therapy (20).
Clinical Markers
An early study investigating the risk factors for bleeding
among patients treated with warfarin found that age ≥65 years,
prior stroke, history of gastrointestinal bleeding, presence of
serious comorbidity (such as recent myocardial infarction or
renal impairment) and AF were important predictors (133).
However, the study was limited by a small sample size and
heterogenous cohort. Hughes et al. performed a systematic
review of nine studies reporting on anticoagulation-related
bleeding complications in AF to demonstrate that increasing
age, uncontrolled hypertension, prior myocardial infarction or
ischemic heart disease, prior stroke, anemia, history of bleeding,
and concomitant use of other drugs (e.g., antiplatelets) were
TABLE 5 | Risk factors for anticoagulation-related bleeding.
Risk factor Possible risk factor
Clinical
markers
History of bleeding
Antiplatelets or NSAID use
Excess alcohol
Uncontrolled hypertension
Increasing age
Malignancy
Prior stroke
Vascular disease
Race/ethnicity (non-white)
Choice of anticoagulant
Diabetes mellitus
Female sex
Prior falls
Thyroid disease
Prior MI or known IHD
Biological
markers
Poor anticoagulation control
(high INR or reduced TTR)
Liver dysfunction
Renal dysfunction
Anemia
Reduced platelet count
or function
Interleukin-6
von Willebrand factor
Growth differentiation factor-15
Troponins
Genetic
marker
CYP 2C9 polymorphism
CYP, cytochrome P450; IHD, ischemic heart disease; INR, international normalized ratio;
MI, myocardial infarction; NSAID, non-steroidal anti-inflammatory drug; TTR, time-in-
therapeutic range.
independent risk factors for bleeding (134). Unlike previous
studies (135, 136), diabetes mellitus and sex were not found
to be important predictors. Conversely, age and concomitant
use of antiplatelets have been consistently shown to significantly
increase the risk of anticoagulation-related major bleeding
(129, 135–137). Potential explanations for the increased risk
of bleeding with age may relate to changes in metabolic
clearance, higher prevalence of comorbidities, degenerative
vascular changes, polypharmacy, and cognitive decline (138).
Meanwhile, concomitant use of antiplatelets will interfere with
additional hemostatic pathways that are necessary to prevent
bleeding. Additional anticoagulation-related bleeding risk factors
that have previously been described include excess alcohol intake
and thyroid disease (136, 139).
Falls
Prior falls is perceived as a risk factor for anticoagulation-
related bleeding, especially in elderly patients. Gage et al.
demonstrated a significantly increased risk of ICH associated
with the use of warfarin in AF patients deemed at high-
risk of falls (140). Based on this, such patients are often
deprived of anticoagulant treatment for stroke prevention with
TABLE 6 | Bleeding risk scores in AF.
Risk factors ABC-
bleeding
(129)
ATRIA
bleeding
(130)
HAS-
BLED
(18)
HEMORR
2HAGES (131)
ORBIT
(131)
Antiplatelets or
NSAID use
x x
Diabetes mellitus
Excess alcohol x x
Excessive falls risk x
Females x
History of bleeding x x x x x
Hypertension x x x
Elderly patients x x x x x
Malignancy x
Previous stroke x x
Abnormal liver
function
x x
Abnormal renal
function
x x x x
Anemia x x x x
Labile INR (TTR
<60%)
x
Raised GDF-15 x
Raised hsTrop x
Reduced platelet
count or function
x
CYP 2C9
polymorphism
x
Total score 45 10 9 12 7
CYP, cytochrome P450; GDF-15, growth differentiation factor-15; hsTrop, high-sensitivity
troponin; INR, international normalized ratio; NSAID, non-steroidal anti-inflammatory drug;
TTR, time-in-therapeutic range.
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the assumption that it is harmful. However, it is important
to recognize that within the same study, there was overall
improvement in clinical outcomes among patients at high-
risk of falls who received anticoagulation therapy, despite the
increased risk of ICH. In a separate study involving 7,156
patients with AF, a history of falls was independently associated
with a 3.3-fold increased risk of major bleeding (141). The
authors remarked that assessment of “actual falls” may be more
clinically useful than the “falls risk.” This may provide an
explanation for lack of association between falls and major
bleeding events in a prospective study involving 515 patients on
oral anticoagulation, where falls risk was used (142). Overall,
the current evidence indicate that a history of falls may be an
important risk factor for major bleeding but that this should
not be the sole deterrent for anticoagulation in AF. In support
of this, an earlier study by Man-Son-Hing et al. found that
patients would need to fall an estimated 295 times per year for
the risk of serious bleeding to outweigh the beneficial effects of
warfarin (143).
Malignancy
Presence of a malignant disease has been associated with
increased anticoagulation-related bleeding. A study by Gitter
et al. found that patients with a malignant condition at the
time of warfarin initiation had a 4-fold greater risk of major
hemorrhage during a 28-month follow-up period (144). Results
from a secondary analysis of a prospective RCT demonstrated
that the higher risk of bleeding was also observed with other
anticoagulants such as heparin and danaparoid (145). Despite
the overall increased risk of anticoagulation-related bleeding with
malignant conditions, there exist variations in terms of safety
and efficacy between the different options for anticoagulation.
In general, low-molecular weight heparin has a similar safety
profile to VKA and is superior for prevention of recurrent
thromboembolism (146, 147). Non-vitamin K antagonist oral
anticoagulants are a more convenient option to low-molecular
weight heparin but may be associated with a higher risk of major
bleeding with comparable effectiveness (147–149). Therefore,
patients with malignant conditions who require anticoagulation
therapy should be commenced on either low-molecular weight
heparin or NOACs.
Ethnicity
A previous study of 28,628 patients from the GARFIELD-AF
registry demonstrated that those with an Asian background had
reduced risk of major bleeding compared to other ethnicities
(150). However, subsequent studies have found that while the risk
of ICH is higher among non-whites in general, it was up to 4-fold
higher in Asians compared to whites (151, 152). Furthermore, the
complication was associated with worse outcomes in this group
of patients (153). Given the current evidence, additional attention
should be directed toward other modifiable bleeding risk factors
in Asian patients commencing anticoagulation therapy. It may
also be appropriate to consider NOACs in the first-instance as
these have been found to be safer alternatives to VKA in this
cohort (154).
Weight
Body weight is known to influence the distribution and clearance
of anticoagulants (155). Therefore, there were concerns about
the safety (and efficacy) of these medications in patients with
extremes of body weight. However, studies on this topic have
produced reassuring results. The risk of anticoagulation-related
bleeding appears similar in underweight, and overweight or
obese patients compared to those with normal body weight
(156, 157). In fact, some studies have suggested that obesity may
even be associated with reduced rates of bleeding (158–160).
Furthermore, patients with obesity and AF who were treated with
a NOAC had lower risk of thromboembolism, leading to the term
“obesity paradox” (156–158).
Biological Markers
There are several biomarkers that may help predict
anticoagulation-related bleeding. Some of these are linked
to stroke risk and have already been described above (e.g.,
renal failure, IL-6, vWF). Perhaps one of the most important
biomarkers associated with the use of VKA is the intensity
of anticoagulation, measured as the international normalized
ratio (INR). Higher INR levels have been found to increase
the risk of anticoagulation-related bleeding, with relative risks
(RR) for INR ≥4.5 of 7.9 (95% CI, 5.4–11.5) compared to
INR <4.5 (127). It is estimated that every one unit increase
in INR above 2.5 was associated with a 2-fold increased
risk of mortality (161). Therefore, every effort should be
taken to maintain the INR of AF patients within pre-defined
ranges, often between 2 and 3 (20). However, absolute INR
levels alone can be misleading as a significant proportion
of major bleeds occur despite the INR being in therapeutic
range (162). More recently, INR variability has emerged
as a more reliable assessment method for bleeding risk. A
“labile INR” as determined using time-in-therapeutic range
(TTR) is strongly linked to future bleeding events (163–
165). However, there are several limitations of TTR that are
worth bearing in mind (166, 167). Firstly, it assumes a linear
relationship between INR measurements which may not be
true. Secondly, it does not inform on short-term risks associated
with extreme deviations in INR. Lastly, it fails to account
for individuals with “missed” monitoring periods who may
represent a group at higher risk of bleeding due to reasons such
as non-adherence.
Given the importance of the liver and kidneys in regulating
pharmacokinetics of drugs and maintaining hemostasis, it is
inevitable that fluctuations in the functions of these organs
could negatively impact on anticoagulation-related bleeding. A
prospective, observational study of 8,466 AF patients treated
with either VKA or NOACs suggests that both abnormal
renal and liver functions were associated with increased risk
of major bleeding (168). The study authors defined abnormal
renal function as serum creatinine >2.3 mg/dL (200 µmol/L),
prior renal transplantation or receiving chronic dialysis, and
abnormal liver function as cirrhosis, elevated liver transaminases,
or alkaline phosphatase >3 times above the upper limit of
normal, or bilirubin >2 times above the upper limit of normal.
Similar findings were reported in a separate large cohort study
Frontiers in Medicine | www.frontiersin.org 14 February 2020 | Volume 7 | Article 54
Ding et al. Risk Assessments in AF
of 7,141 AF patients receiving rivaroxaban (169). Furthermore,
Banerjee et al. reported that lower levels of eGFR were related
to a greater risk of major bleeding over a study period of 2.5
years (61).
Anemia has also been linked to increased bleeding risk (133,
134, 170). The underlying mechanism remains unclear but there
is some evidence to suggest that platelet aggregation is impaired
by a reduced red blood cell count (171). Furthermore, the anemia
may indicate concealed bleeding that becomes manifest with
anticoagulation therapy.
The use of IL-6 as a predictor of anticoagulation-related
bleeding remains controversial. A large cohort study in
AF patients found that IL-6 was independently associated
with bleeding following adjustment for clinical risk factors
and other biomarkers (troponin, NT-proBNP, and cystatin-
C) (59). Meanwhile, although a separate large cohort study
initially demonstrated the relationship between IL-6 and
bleeding, the results were not statistically significant once
other biomarkers were taken into account (172). Neither of
these studies found CRP to be important in the relationship
with bleeding.
Similar to the stroke findings as discussed above, the
study by Janion-Sadowska et al. found no association between
thrombocytopenia (platelet count <100 × 109/L) and risk of
bleeding (53). In contrast, Park et al. reported that patients with a
platelet count <100 × 109/L had a significantly increased risk of
bleeding events compared to those with a normal platelet count
[HR 2.19 (95% CI, 1.77–2.70)] (52). Despite limited evidence on
the matter, it seems likely that a low platelet count could increase
the risk of bleeding in AF.
In addition to the biomarkers above, there are several
others that have been associated with anticoagulation-related
bleeding including vWF, high-sensitivity troponin, and growth
differentiation factor-15 (marker of oxidative stress). Roldan et al.
showed that patients with high levels of vWF had a 4.5-fold
increased risk of major bleeding (69). Using the ARISTOTLE
cohort, Hijazi et al. demonstrated that both high-sensitivity
troponin and growth differentiation factor-15 were the strongest
predictors of major bleeding when compared to traditional risk
factors such as age, hemoglobin, previous bleeding, congestive
heart failure, previous stroke or TIA, hypertension, and diabetes
mellitus (129). Studies on NT-proBNP have not found it
to be useful for predicting anticoagulation-related bleeding
(62, 65, 66). Overall, there is limited research to support
the “real world” role of these biomarkers in relation to
bleeding risk assessment, given that bleeding risk is dynamic
and changes with addressing modifiable risks, and that many
biomarkers are non-specific and likely to reflect a sick patient or
“sick heart.”
Genetic Markers
Polymorphism of cytochrome P450 2C9 has been linked to
an increased risk of major bleeding through its effects on the
metabolism and action of warfarin (173). It may also have
important implications on warfarin dose requirements (174).
However, as mentioned above, there is currently limited evidence
on the role for genetic markers in AF.
LIMITATIONS OF RISK SCORES
Risk scores are useful as they provide a rapid tool to guide
treatment decisions in AF and highlight bleeding risk factors
that deserve attention. However, it is important to recognize
that the risk scores in AF have been simplified to provide
physicians with a reliable yet useable tool for daily clinical
practice. As a result, most are subject to several limitations and
are at best, only modestly robust at predicting individual stroke
risk (175).
First, not all risk factors may be included in certain
risk scores. Second, they use a “one size fits all” approach
and do not account for the heterogenous nature within the
AF population. Third, they fail to adequately consider the
differential weight of individual risk factors. Fourth, they
fail to consider the degree or severity of individual risk
factors. Fifth, many risk scores were developed using older
definition of diseases that may have subsequently evolved over
time. Finally, studies have often correlated stroke occurrences
during long periods of follow-up to risk factors measured at
baseline, and risk changes with increasing age and incident
risk factors. Indeed, recent attention has been directed toward
the dynamic nature of risk profiles in AF patients (176–
178). Chao et al. found the majority of patients with AF
(89.4%) developed ≥1 new risk factor(s) prior to presenting
with an ischemic stroke (178). Indeed, a change in CHA2DS2-
VASc score was demonstrated to be strongly predictive of
ischemic stroke. The study highlights the importance of
regular stroke risk assessments in AF. Therefore, stroke and
bleeding risk stratification should be undertaken by clinicians
as a continuous process with specific focus on preventing
the development of additional risk factors. Furthermore, in
addition to the dynamic nature of risk, therapeutic options
for AF are expanding. As more effective and safer therapies
are introduced, we may need to re-evaluate the threshold for
initiating anticoagulation.
CONCLUSION
In conclusion, there are a variety of clinical, electrical,
biological, and genetic markers to guide stroke and bleeding
risk assessments in AF. Furthermore, risk schemas provide a
structured, standardized, and rapid tool for this purpose.
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